by Barry101 | Sep 19, 2024 | Press Release
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no severe adverse events or dose-limiting toxicities OCALA, Fla., Sept. 19,...
by Barry101 | Sep 11, 2024 | Press Release
Company is planning a follow-up clinical trial with a focused subject population of moderate-to-severe Post-COVID-related fatigueOCALA, Fla., Sept. 11, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that an analysis of the...
by Barry101 | Aug 20, 2024 | Press Release
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and two other drugs OCALA, Fla., Aug. 20, 2024 — AIM ImmunoTech Inc. (NYSE...
by Barry101 | Aug 16, 2024 | Press Release
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August 16th at 8:30 AM ET OCALA, Fla., Aug. 16, 2024 —...
by Barry101 | Aug 13, 2024 | Press Release
OCALA, Fla., Aug. 13, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q2 2024 operational and financial...
